CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism.
By M. Febbraio, D. Hajjar, R. Silverstein. Journal of Clinical Investigation, 2001
1,151 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology, Pharmacology
View Paper: https://www.semanticscholar.org/paper/9b0f150a0444016ab4be889413ed67eb3f512210
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
- W. Charman
- J. Luiken
- P. Murray
- Christopher K. Glass
- Colin W. Pouton
- A. Bonen
- Christopher J. H. Porter
- S. Charman
In Pharmacology
- W. Charman
- P. Murray
- Colin W. Pouton
- Christopher J. H. Porter
- S. Charman
- H. Williams
- TA Wynn
- R. Shanker
Citations in the corpus
- Robust single particle tracking in live cell time-lapse sequences (2008, background): “At rest, CD36 is thought to exist as quiescent monomers, which are activated and internalized in response to oligomerization by multivalent ligands like oxidized LDL and malaria-infected red blood cell”
- Protective and pathogenic functions of macrophage subsets (2011, background): “These pathogenic macrophages also express higher levels of scavenger receptors and CD36, which augments the uptake of modified forms of low-density lipoprotei”
- Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. (2010, background): “IIB) on fatty acid uptake by rat adipocytes (172–174) led to the identification of an integral membrane protein designated (putative) membrane fatty acid translocase (4) that appeared identical to leukocyte cluster-of-differentiation antigen CD36 (glycoprotein IV), now recognized as a class B scaven”
- Triggers, targets and treatments for thrombosis (2008, background): “It is well established that CD36 functions as a scavenger receptor at the surface of macrophages: it binds to oxidized low-density lipoproteins, resulting in the formation of foam cells and therefore contributing to the development of atherosclerotic plaque”
- Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs (2022, background): “CD36, in turn, recognizes anionic phospholipids, fatty acids, collagen, and oxidatively modified lowdensity lipoprotein (oxLDL) [111].”
- The macrophage foam cell as a target for therapeutic intervention (2002, background): “Macrophage scavenger receptors Macrophages express several scavenger receptors that are capable of taking up oxidized LDL, including scavenger receptor A, scavenger receptor BI (SR-BI), CD36, CD68 and scavenger receptor for phosphatidylserine and oxidized lipoprotei”
- ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule independently of its catalytic activity (2010, background): “Short sequences present in the N-terminal domain, especially in the thrombospondin type 1 repeats (TSR1), are released by ADAMTS-1 [5] and inhibit angiogenesis by interacting with the CD36 scavenger receptor [6–8].”
- Strategies to Address Low Drug Solubility in Discovery and Development (2013, background): “Subsequently, several lipid transporters have been identified (Niot et al., 2009) that interact specifically with free lipid (e.g., FA, cholesterol, PL) (Endemann et al., 1993; Febbraio et al., 2001; Krieger, 2001; Thuahnai et al., 2001; Rajaraman et al., 2005).”
- Exosomes with Immune Modulatory Features Are Present in Human Breast Milk1 (2007, background): “CD36 on cells has been reported to have diverse functions such as mediation of phagocytosis, cell adhesion, and binding of oxidized low-density lipoproteins (31).”